OnTarget Group
Dr. Silve Vicent

The project is aimed at the characterization of new inhibitors to the KRAS pathway for the treatment of tumors with KRAS mutations building on previous work by the group (Entrialgo-Cadierno et al, Molecular Cancer, 2013; Erice et al, Clin Cancer Res 2023; Lasheras-Otero, J Inves Dermat 2022; Vallejo et al, J Hepatology 2021; Valencia et al, J Clin Invest 2020; Vallejo et al, Nat Comms 2017; Roman et al, Mol Cancer 2018; Roman et al, Cancer Res 2018). The project will provide opportunities to interact with academic and industrial partners.

The project will require, among other tasks: generation of new tumor models using the CRISPR/Cas9 technology, development of CRISPR/Cas9 los-of-function screens, functional characterization of new elements within the KRAS network, testing of novel combinatorial therapies, and dissection of the mechanism of action for nominated genes and/or drug combinations using high-throughput (scRNAseq, RNAseq, ATACseq, multiplex cytometry and IF, proteomics and/or metabolomics) and focused approaches.

CANDIDATE’S REQUIREMENTS
- PhD in biological or biomedical sciences.
- Self-motivated, resilient, autonomous person with team work and communication skills, and the ability to lead the project since its inception.
- Background in Cancer Biology (e.g. drug resistance) and/or Immunotherapy is preferred.
- Training in animal work is a plus.
- Publication record to compete for additional fellowship applications (e.g. Marie Curie actions, Juan de la Cierva, …) is mandatory (at least one first-author publication).

APPLICATION SUBMISSION
Interested applicants should send a cover letter describing past experience and interests to: silvevicent@unav.es.
Applications will be considered until November 30, 2023.

ABOUT US!
We are a research center committed to excellence in translational research, based on novel biological knowledge and aimed at finding therapeutic solutions to patients’ needs.

We are the biomedical research center of the Universidad de Navarra, Spain. With our academic status we work on a non-profit basis to reinvest the surpluses in the progress of our research and to fulfill our mission of service to patients and society.

TECHNOLOGICAL PLATFORMS
Cytometry
We use immunphenotypic techniques to determine the characteristics of particles or cells in suspension.

Genomics
State-of-the-art genome sequencing technology in an accurate and agile manner.

Animal Production and Experimentation
Support for all research projects that require the use of animals.